Prostate Cancer News Archive
Men and women who smoke are at 2.3-fold and 2.7-fold increased risk of bladder cancer compared with non-smokers.
Prostate and lung cancer expected to emerge as the most common types by 2030.
The new statement emphasizes shared decision-making on screening for men aged 55 to 69 years who are at average risk for prostate cancer.
Canadian study shows that nearly all men undergoing radical prostatectomy in Eastern Ontario in recent years have clinically significant prostate cancer.
Men with Gleason score (GS) 4+3 prostate cancer have a 3-fold higher risk of distant metastasis at diagnosis than those with GS 3+4 PCa.
Obese men with non-metastatic castration-resistant prostate cancer have a 21% decreased risk of death compared with normal weight men, according to a study.
Findings for both men and women with a false-positive prostate or breast cancer test result.
Increased incidence of malignant disease, specifically prostate, melanoma, pancreas, breast cancers
Sexual dysfunction was a chief complaint among survey respondents with prostate cancer.
Myocarditis with ICIs may be more common than initially thought; responds to higher steroid dosages
A novel component of an interventional program was cognitive-behavioral counseling administered in a group setting to promote behavioral change.
In a study, race independently predicted prostate cancer-specific mortality beyond a number of risk factors, including health insurance status.
Low-dose AA with low-fat breakfast had greater effect on PSA; similar effect to standard dose
Study identifies which PCa patients with positive lymph nodes may have improved survival with the addition of adjuvant radiotherapy to androgen-deprivation therapy.
Researchers concluded that a greater than 90-day interval from prostate biopsy to radical prostatectomy increases the risk of biochemical recurrence among men with Gleason 3+4 disease.
Study documents a drop in the incidence of de novo metastatic PCa from 1980 to 2011 in the United States.
New study shows that men are at lower risk of prostate cancer for years after they stop taking the medication.
In a large international trial, pre-biopsy MRI scans spared 28% of men from having to undergo a biopsy and resulted in a lower detection of clinically insignificant cancers vs standard biopsy.
Researchers observed reductions in biochemical failure and distant metastasis rates in patients who had dose-escalated radiation therapy.
However, mortality higher with conservative therapy in locally advanced, non-metastatic prostate cancer.
Findings from a large study of men in the United Kingdom do not support single PSA testing for population-based screening.
In a study, extremely dose-escalated radiotherapy combined with androgen deprivation therapy offered the best cancer-specific survival among men with Gleason 9-10 prostate cancer.
In a 12-month study, men with prostate cancer treated with ADT reported more nocturia episodes than men with prostate cancer treated with prostatectomy alone and men with no history of cancer.
Multiparametic MRI findings added to conventional clinical predictors decreases the number of false-positive biopsy results without increasing the number of clinically significant tumors left undiagnosed, study finds.
Apalutamide prolonged metastasis-free survival by 2 years compared with placebo.
Added to hormone therapy, docetaxel offers a cost effective way to prolong hormone-sensitive disease and improve quality of life years, especially among men with non-metastatic disease, study finds.
Trials sponsored by academic investigators, cooperative groups more likely to use these criteria
In a small phase 2 study of overweight men with recurrent prostate cancer, consuming less than 20 grams of carbohydrates a day resulted in profound weight loss.
Metastasis and death are more likely to occur among patients with relatively high PSA levels at diagnosis of nmCRPC and rising PSA levels during follow-up.
Multiparametric MRI has high positive and negative predictive values for extracapsular extension, seminal vesicle invasion, lymph node involvement, and high-risk Gleason score.
In a study, nearly 20% of radical cystectomy patients were readmitted for complications within 90 days compared with 1.9% and 5.9% for radical prostatectomy and radical nephrectomy, respectively.
Among men who had PSA failure following radiation therapy for localized PCa, those with a long PSA doubling time had an increased risk of PCa mortality if they started androgen-deprivation therapy later.
Black men undergoing radical prostatectomy for prostate cancer are more likely to have indications for adjuvant radiotherapy compared with white men.
Statin use is associated with greater overall survival among men with metastatic castration-resistant prostate cancer and improved survival among patients with high-risk prostate cancer.
In a study, a negative confirmatory prostate biopsy in prostate cancer patients on active surveillance predicts a lower risk of progressing to treatment.
In separate studies, apalutamide and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.
In a study of hypogonadal men, those who received testosterone therapy had a lower incidence of prostate cancer than those who did not.
The technology facilitates teaching of advanced surgical skills, delivery of care to underserved
The investigators observed no difference in mortality between BT alone and BT plus ADT and/or EBRT supplemental therapy.
In a study, the 17-year prostate cancer-specific and biochemical failure-free survival rates were 97% and 79%, respectively.
Adjuvant radiotherapy was associated with lower risks for biochemical failure and distant metastases and increased overall survival in patients with adverse pathologic features found after radical prostatectomy.
Following radical prostatectomy, higher BMI increases risk of recurrence for prostate cancer.
Androgen-deprivation therapy without estrogen is associated with a significant 43% increased risk of thromboembolic events, meta-analysis shows.
In a meta-analysis, the risk of infectious complications was 78% lower with fosfomycin trometamol versus fluoroquinolones in men undergoing TRUS-guided prostate biopsy.
In a single center study, asymptomatic bacteriuria resolved before prostate biopsy, without additional treatment.
Polygenic hazard score can guide screening based off predicted prostate cancer diagnosis age.
A study showed longer survival among patients with metastatic hormone-sensitive prostate cancer who achieved a PSA level of 0.2 ng/mL or less 7 months after initiating ADT.
Study finds that closely adhering to a Mediterranean-style diet possibly protects men from aggressive and advanced prostate cancer.
Each 10 mg/dL increase in serum levels of total and HDL cholesterol are associated with a significant 5% and 14% increased risk of high-grade PCa, respectively.
Patient age 70 years and above is an independent risk factor for perioperative morbidity, according to data from a national cohort.
Patients who have to travel longer distances for prostate cancer treatment are more likely to receive stereotactic body radiotherapy.
Rates of erectile dysfunction and urinary incontinence at 1, 2, and 3 years after radical surgery are not higher among men who have multiple prostate biopsies while on active surveillance for prostate cancer.
A rotating shift schedule appeared the most risky.
Among patients with high-risk prostate cancer, investigators observe no significant difference in cancer-related death risk between radiotherapy and radical prostatectomy.
An analysis of an intervention arm of the PLCO Cancer Screening Trial evaluated the risk of prostate cancer relative to dietary consumption of isoflavones, a dietary compound found in some plant foods.
Male patients with mCRPC and seizure risk factors did not have increased seizure incidents when taking Enzalutamide.
Recent research suggests that P. acnes, which is associated with acne vulgaris, is more likely to be present in the prostatic tissue of patients with the disease than in healthy individuals.
A negative mpMRI is associated with a higher risk for PSA recurrence and metastasis following salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Cancer survival was greatly skewed toward patients with Medicare or private insurance.
Investigators who compared 4 active surveillance cohorts found that biennial prostate biopsies appear to be an acceptable alternative to annual biopsies.
Results of a large prospective study show that appropriate use of the phi test can improve physicians' ability to diagnose and manage patients.
Assessments of androgen receptor, glycolysis prognostic in castration-resistant prostate cancer.
Hypogonadal men who received testosterone replacement therapy had a lower incidence of prostate cancer than those who did not, and their cancers were less severe.
In a prospective study, mCRPC patients placed on enzalutamide after their disease progressed while on abiraterone therapy had a median radiographic progression-free survival of 8.1 months.
In a small but meaningful number of patients, Gleason pattern 4 disease missed by MRI and systematic biopsy is present outside the focal ablation zone.
The variant HSD3B1 allele increases the likelihood of metastasis in men receiving androgen-deprivation therapy for biochemically recurrent disease after radiotherapy for localized PCa.
Non-metastatic prostate cancer patients are more likely to die from causes other than the disease.
Exposure to androgen-deprivation therapy was associated with a nearly 2-fold increased risk of heart failure among men without pre-existing cardiovascular disease.
Biochemical failure and prostate cancer-specific mortality rates were 13.3% and 4.9% at 10 years, respectively.
Pathologic stages T3a and T3b versus T2a were associated with 8.45 and 7.1 times increased risk of biochemical recurrence on multivariable analysis.
The later a man's testosterone level dropped below 12.1 nmol/L, the lower his lifetime risk for prostate cancer.
Researchers find BRCA2 mutations are associated with worse outcomes among men with mCRPC.
Use of intensity-modulated radiation therapy for prostate cancer increased from 3.5% to 64% from 2002 to 2012.
In a case-control study, men who had ever used non-steroid anti-inflammatory drugs had a 23% decreased risk of prostate cancer.
Use of active surveillance for very low-risk prostate cancer rose from 11.6% of patients in 2010 to 27.3% in 2013, study finds.
Following curative treatment for localized PCa, 5-year PCa-specific survival rates are higher for patients with initial lymph node or locoregional metastases versus initial metastases in bone only or in multiple sites.
Findings from this comparative study indicate a favorable failure-free survival and progression-free survival with Standard of Care plus abiraterone acetate and prednisone.
PSA levels of 10 ng/mL or higher in men who have biochemically recurrent PCa after radical prostatectomy and a PSADT less than 12 months are at imminent risk for metastatic disease.
The researchers found that there was no difference between the 6- and 2-fraction groups in baseline and post-implantation IPSS scores.
A European trial found a survival benefit from PCa screening and a US trial did not, but a new analysis finds that both trials provide compatible evidence that screening decreases PCa mortality.
In a study, the risk for heart failure was 81% higher among patients who received androgen deprivation therapy.
Patients are more likely to receive intensity-modulated radiation therapy if they are managed by urology practices with an ownership interest in the modality, study finds.
The six-month cumulative incidence of myocardial infarction was 2.0% and 0.7% in patients with cancer and controls, respectively.
Prostate cancer patients accurately report their comorbidities, and participants in cancer clinical trials report more adverse events than trial investigators.
Improvement in BMD was seen with denosumab, which also reduced the incidence of new radiographic vertebral fractures in one high-quality trial.
Men with 1 high-risk factor experience better outcomes following treatment than those with 2 or 3 high-risk factors, study finds.
Study of men with intermediate- or high-risk prostate cancer finds facility-level racial disparity in use of definitive treatment.
A detectable PSA nadir combined with shorter time to nadir after prostate cancer surgery is associated with a higher risk of biochemical recurrence.
63% of patients were managed initially with observation.
Nearly 1 in 3 patients diagnosed with Gleason 3+4 favorable intermediate-risk prostate cancer had their disease upgraded or upstaged at radical prostatectomy.
Most common infection in prostate biopsy was E. coli, followed by mild bleeding.
Throughout the study, a total of 115 lobes were treated and 82% achieved absent clinically significant cancer.
Researchers calculated that the absolute increase in lifetime risk of prostate cancer associated with vasectomy was just 0.6%.
Study reveals that a quarter of men with low-volume intermediate-risk prostate cancer had adverse pathologic features found at radical prostatectomy.
Every additional 4 inches of height was associated with a 21% increase in risk of being diagnosed with high-grade prostate cancer, and a 17% increased risk of dying from prostate cancer.
Randomized trial found no significant difference in all-cause and cancer-specific survival between radical prostatectomy and observation for localized prostate cancer.
Across time, only African-American race correlated with greater regret.
Men with prostate cancer and at least one additional primary cancer are enriched for harboring a germline deleterious mutation in a cancer-predisposing gene.
Over a 10-year period, radical prostatectomy use increased steadily while radiotherapy use declined
Both findings on biopsy also predict a lower odds of high-grade cancer.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)